Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alefacept + pneumococcal vaccine polyvalent
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
The combination of alefacept and polyvalent pneumococcal vaccine refers to a clinical study context evaluating the immune competency of patients undergoing treatment for chronic plaque psoriasis. Alefacept (Amevive) is a recombinant dimeric fusion protein consisting of the extracellular CD2-binding portion of human leukocyte function-associated antigen-3 (LFA-3) linked to the Fc portion of human IgG1. It selectively targets and depletes memory-effector T cells (CD45RO+) by binding to the CD2 receptor, thereby reducing the inflammatory response in psoriasis. The polyvalent pneumococcal vaccine is a non-conjugated vaccine containing purified capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae. The Phase 4 study conducted by Astellas Pharma was designed to determine if the T-cell modulating effects of alefacept interfered with the B-cell mediated antibody response to the pneumococcal vaccine, ensuring that patients remained protected against bacterial infections during biologic therapy.
- Brand names
- Pneumovax 23Pneumovax23Pneumovax-23
- Other names
- LFA-3/IgG1 fusion protein23-valent pneumococcal polysaccharide vaccinePPV-23PPV23PPV 23
02
Targets
CD2 (T-cell Surface Antigen CD2)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)CD58 (Leukocyte function-associated antigen 3)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on alefacept + pneumococcal vaccine polyvalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alefacept + pneumococcal vaccine polyvalent.